Stretching Low-Dose Rituximab Doses May Be Safe

Credibility

Interest

Key Takeaway

For people with relapsing MS who were stable for at least one year on low-dose rituximab, stretching infusions out to every 18–24 months did not raise short-to-medium term disease activity compared to keeping them every 6–12 months.

What They Found

Researchers looked at 1,052 people with relapsing multiple sclerosis (MS) who had no relapses, new MRI lesions, or disability progression during their first year on low-dose rituximab (500 mg).About 44% of these people had at least one infusion interval extended to 18–24 months, while the rest stayed on 6–12 month dosing.Over 3–5 years of follow-up, relapses or new MRI activity were uncommon (around 2–3% overall), and most people kept being disease-free by the study measures.After using statistical methods to fairly compare the groups, extending dosing to 18–24 months was not linked to more disease activity than staying on 6–12 month intervals.Because higher total doses of rituximab can raise infection risk, stretching the time between low-dose infusions could lower cumulative exposure without increasing short-term disease activity for people already stable on treatment.

Who Should Care and Why

People with relapsing MS who have been stable (no relapses, no new MRI lesions, no worsening disability) for at least one year may benefit, because fewer infusions could mean fewer clinic visits and less drug exposure.Caregivers may notice practical benefits like fewer appointments and reduced travel or scheduling burden when dosing is safely spaced out.Neurologists and MS nurses can use this information to discuss personalized plans that balance disease control and infection risk — like comparing it to taking less frequent doses of a maintenance medicine once things are under control.Patients worried about infections or side effects from repeated infusions might find it reassuring that, in this study, less frequent low-dose treatment did not raise short-term disease activity.This finding could affect daily life by reducing time spent getting infusions, lowering costs or time off work, and possibly lowering infection risk from repeated immune suppression, but decisions should be individualized with your care team.

Important Considerations

This study looked only at people who were already stable for a year on rituximab, so the results don’t apply to people who still have active disease or who are new to the drug.The follow-up was 3–5 years and the study was retrospective (looking back at real-world records), so rare longer-term risks or small differences might not have been detected.Because this was not a randomized trial, doctors chose who had extended intervals; although the researchers adjusted for those differences, some uncertainty remains and any change should be discussed with your neurologist.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials MS Progression

Article Topics:

Multiple sclerosisde-escalationdisease modifying therapiesextended dosingrituximab

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News